Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A NSCLC
NCT06385262Phase 2Recruiting
- Sponsor
- Duke University
- Start
- Mar 2025
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alirocumab in non-small cell lung cancer (NSCLC), sponsored by Duke University. Started Mar 2025; status: recruiting.
02
Drugs
alirocumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06385262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385262.